Announced its financial results for the three months ended June 30, 2026. All amounts are in thousands of United States dollars unless otherwise stated. Q2 2026 revenue was $14.7 million, Adjusted EBITDA was $4.7 million and cash from operations was $2.9 million, compared to $14.2 million, $5.2 million and $4.6 million, respectively. HLS Therapeutics Inc. shares T.HLS are trading up $0.07 at $3.90.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.